Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 4/20 | 0.55 |
| ▸ | SI | P14410 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379044 | 1.00 | FUCA1 (0.55) | FUCA1SIGBA1GABRR1MGAM | |
| SCHEMBL28814677 | 0.97 | — | — | |
| SCHEMBL28814676 | 0.97 | — | — | |
| SCHEMBL28814275 | 0.97 | — | — | |
| SCHEMBL28187858 | 0.97 | — | — | |
| SCHEMBL28814256 | 0.97 | — | — | |
| SCHEMBL26664707 | 0.97 | — | — | |
| SCHEMBL28814332 | 0.97 | — | — | |
| SCHEMBL21105130 | 0.83 | FUCA1 (0.63) | FUCA1SIGBA1GABRR1MGAM | |
| SCHEMBL18460913 | 0.83 | FUCA1 (0.63) | FUCA1SIGBA1GABRR1MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654779-B1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INST FOR CANCER RES LTD (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20120093875-A1 | AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2409966-A1 | AMINOCYCLITOL COMPOUNDS, PROCEDURE FOR THE OBTAINMENT AND USES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-01-25 | — | — | EP | disclosed |
| WO-2005092834-A1 | PROCESSES FOR THE PURIFICATION OF VOGLIBOSE AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092834-A1 | PROCESSES FOR THE PURIFICATION OF VOGLIBOSE AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093875-A1 | AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES | AADAT, NFATC1, PBK | FUCA1 263/4885SI 254/4885GBA1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.